http://www.cnr.it/ontology/cnr/individuo/prodotto/ID209881

Improved survival in limited scleroderma-related pulmonary artery hypertension (Articolo in rivista)

Type

Label

Improved survival in limited scleroderma-related pulmonary artery hypertension (Articolo in rivista) (literal)

Anno

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

Alternative label

Carlo Marini3, Bruno Formichi1,2, Carolina Bauleo1, Claudio Michelassi, Roberta Pancani, Renato Prediletto1,2, Massimo Miniati5, Giosuè Catapano1, Simonetta Monti1,2, Francesca Mannucci1, Antonio Tavoni4, Anna D'Ascanio4, Luigi Emilio Pastormerlo1, Alberto Giannoni1, Carlo Giuntini (2013)
Improved survival in limited scleroderma-related pulmonary artery hypertension
in Internal and emergency medicine (Online); Springer, Milano-Heidelberg-New York (Italia)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Carlo Marini3, Bruno Formichi1,2, Carolina Bauleo1, Claudio Michelassi, Roberta Pancani, Renato Prediletto1,2, Massimo Miniati5, Giosuè Catapano1, Simonetta Monti1,2, Francesca Mannucci1, Antonio Tavoni4, Anna D'Ascanio4, Luigi Emilio Pastormerlo1, Alberto Giannoni1, Carlo Giuntini (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

Rivista

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

1. Fondazione Regione Toscana \"G. Monasterio\", Via G. Moruzzi 1, Ghezzano, 56124, Pisa, Italy 2. Istituto di Fisiologia Clinica del CNR, Via G. Moruzzi 1, Ghezzano, 56124, Pisa, Italy 3. Dipartimento Cardio-Toracico e Vascolare, Università degli Studi, Via Paradisa 2, Pisa, Italy 4. Dipartimento di Medicina Interna, Università degli Studi, Via Roma 67, 56126, Pisa, Italy 5. Dipartimento di Area Critica Medico Chirurgica, Università degli Studi, VialeMorganti 85, 50134, Florence, Italy (literal)

Titolo

Improved survival in limited scleroderma-related pulmonary artery hypertension (literal)

Abstract

Reportedly, patients with scleroderma-related pulmonary hypertension (SSc-PAH) respond poorly to new vasoactive drugs (NVD). Forty-nine SSc-PAH patients underwent right heart catheterization (RHC) and, according to NVD availability, divided as follows: Group 1 (n = 23, from 1999 to 2004, poor availability), and Group 2 (n = 26, from 2005 to 2010, good availability). Before diagnostic RHC, NVD had been given to 30 % of the patients in Group 1, and 58 % of those in Group 2 (p = 0.049). At diagnosis, patients in Group 1 had greater heart dilatation (p < 0.01), higher mean pulmonary artery pressure (p < 0.05), lower pulmonary artery capacitance (p < 0.05), and lower carbon monoxide lung diffusing capacity (DLco, p < 0.05) than those in Group 2. At a median follow-up time of 15.5 months, DLco further decreased in Group 1 (p < 0.05), whereas cardiac index increased in Group 2 (p < 0.05). At 36 months of follow-up, 72.4 % of the patients in Group 2 were still alive as opposed to 30.4 % in Group 1 (p = 0.02). In multivariate analysis, DLco and mixed venous oxygen saturation (SvO2) were independent predictors of survival. A value of DLco <7.2 mL/mmHg/min was associated with a hazard ratio (HR) of 5.3 (p < 0.001); for SvO2 <63.8 %, the HR was 3.7 (p < 0.01).NVD have beneficial effects in patients with SSc-PAH. Both DLco and SvO2 are predictors of survival and may assist in planning treatment. (literal)

Editore